multiple myeloma- a perky dynamism

Views:
 
     
 

Presentation Description

The global Myeloma incidence is on the hike for the past three decades. The trends vary with different geographies. However, the low- and middle- income countries reported a consistent increase from 1990 to 2016 in Myeloma incidence and deaths due to Myeloma.

Comments

Presentation Transcript

slide 1:

Multiple Myeloma - a perky dynamism The global Myeloma incidence is on the hike for the past three decades. The trends vary with different geographies. However the low- and middle- income countries reported a consistent increase from 1990 to 2016 in Myeloma incidence and deaths due to Myeloma. This can be attributed to the lack of standard healthcare facilities in counties that are comparatively lag in socio-economic development. A similar trend has been observed in middle-income countries of the MENA region. A hindrance is observed in delivery of cancer care due to narrow accessibility to general and specialized health care lack of diagnostics and advanced treatments like novel agents radiation oncology and stem cell transplantation which leads to poor outcomes in the MENA region. Therefore recent healthcare equity goals focus on disparities across races and better treatment opportunities. As per DelveInsight’s Multiple Myeloma Market report the pipeline for Multiple Myeloma is highly dynamic with multiple clinical investigations underway interesting even the big market players such as Bluebird Bio Celgene GlaxoSmithKline Bristol-Myers Squibb Abbvie Merck Janssen Amgen Sanofi BioLineRx Takeda Onyx Therapeutics Abbott Karyopharm Therapeutics to sink their teeth into this therapy area with individual or combination trials of novel/approved products. The perks of vigorous investigations will be soon acknowledged by the patients witnessing approval of different therapy alternative in different lines of treatment. Multiple Myeloma is a vast area with no stifle of innovation in its treatment course over the period of time. The treatment regimen includes a multidrug approach with a combination of three or more drugs. The treatment including monoclonal antibodies mAbs proteasome inhibitors PIs immunomodulatory drugs IMiDs will provide great relief to the patients. I In recent times the trend has shifted to other treatment regimes. However these chemotherapy drugs and corticosteroids are still used in combination with one or the other class of treatment. Furthermore two drugs lenalidomide and bortezomib considered to be a standard of care however have not been approved in some African and Middle Eastern countries yet. Additionally stem cell transplantation is routinely available in higher-income countries but is lacking in sub-Saharan Africa and parts of the Middle East. Shockingly South Africa is the only country in sub-Saharan Africa with a stem cell transplant center. Furthermore the recent approval of Aplidin in Australia has opened the door to many other markets in South America Mexico Canada Asia Pacific Middle East and North Africa MENA. In short Myeloma treatment obtainability is inadequate in countries with low socioeconomic development which highlights the need to enhanced access to diagnosis and treatment. Managed Entry Agreements MEA are progressively being executed in the Middle East and North Africa MENA. The countries of MENA regions can be categorized in two classes with one aiding access initiatives that target registration pricing and reimbursement barriers while another creating demand initiatives that aim to drive uptake of drugs upon launch and address issues around awareness affordability and adherence. According to the recent analysis initiatives directing pricing and affordability are frequently recognized in countries which have relatively limited government funding or public healthcare coverage. UAE Egypt Saudi Arabia and Algeria respectively are the most active countries in terms of market access initiatives in the region. MENA region has started witnessing few Managed Entry Agreements although not many accessibility despite being the primary barrier for innovative products. The recent initiatives for market access aim to create an upsurge in capacity and infrastructure in the health care system or simple price discounts rather than value-based partnerships to improve access to innovative treatments in the MENA region. Furthermore resolutions for uninsured or underinsured to declined access entail multiple systemic changes such as amended national guidelines higher and better reimbursement policies negotiation on drug prices value-based pricing evaluating cost-effectiveness and affordability easy permit to generics and biosimilars. Visit https://duphat.ae/ to read more. Source: DelveInsight – www.delveinsight.com

authorStream Live Help